Published 2 days ago • loading... • Updated 2 days ago

Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

On Sunday, April 19, 2026, Rznomics presented interim clinical data for RZ-001 in patients with Hepatocellular Carcinoma at the American Association for Cancer Research Annual Meeting in San Diego, California.
Because Hepatocellular Carcinoma is often diagnosed at advanced stages, there is a critical unmet medical need for innovative therapies providing deeper and more durable responses than current systemic treatments.
Under RECIST-based ORR criteria, the ORR reached 61.5% with a 23% complete response rate, while no Grade 3 or higher adverse events were attributed to RZ-001.
"This oral presentation at AACR represents an important milestone for our lead program RZ-001," said Seong-Wook Lee, Chief Executive Officer of Rznomics, citing encouraging efficacy signals.
Beyond the RZ-001 program, these findings support the clinical applicability of the RNA-based ribozyme platform technology that Rznomics is advancing through collaborations including Eli Lilly.

Insights by Ground AI